Sevda Hızarcı Bulut
Research Subjects
Sevda Hızarcı Bulut has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Bedia Sultan Önal
Giresun University Faculty of Medicine
1 shared publication - Berkan Şahin
Department of Child and Adolescent Psychiatry, Faculty of Medicine, Giresun University, Giresun, Turkey
1 shared publication - Cansu Çobanoğlu Osmanlı
Department of Child and Adolescent Psychiatry, Faculty of Medicine, Giresun University, Giresun, Turkey
1 shared publication - Cansu Ölçer
Department of Child and Adolescent Psychiatry, Giresun University Faculty of Medicine, Giresun, Türkiye
1 shared publication - Elif Kevser Sezer
Department of Child and Adolescent Psychiatry, Giresun University Faculty of Medicine, Giresun, Türkiye
1 shared publication - Gülsüm Yitik Tonkaz
Department of Child and Adolescent Psychiatry, Faculty of Medicine, Giresun University, Giresun, Turkey
1 shared publication
Latest Publications
- 16 July 2025
- Published by Springer Nature in Journal of Psychopathology and Behavioral Assessment
- Vol. 47 (3) , 1-11
Insights into School Refusal: Psychiatric Profiles and Digital Engagement in Children
- 16 July 2025
- Published by Springer Nature in Journal of Psychopathology and Behavioral Assessment
- Vol. 47 (3) , 1-11
Insights into School Refusal: Psychiatric Profiles and Digital Engagement in Children
- 4 June 2020
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 74 (8) , 613-619
Serum nesfatin-1, ghrelin, and lipid levels in adolescents with first episode drug naïve unipolar depression
Background: Major depressive disorder (MDD) is a mental health and emotional disorder that affects children and adolescents worldwide. This study aimed to evaluate serum nesfatin-1, ghrelin, and lipid levels as biological markers of adolescent MDD and their relationship with the severity of depression-anxiety and suicide risk in MDD. Methods:This study included 37 drug naïve adolescents between the ages of 12 and 18 who were diagnosed with a first episode MDD according to the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL) and DSM-V diagnostic criteria. Thirty-three healthy adolescents between the ages of 12 and 18 were included as the control group. The Children’s Depression Inventory (CDI), Screen for Child Anxiety Related Disorders (SCARED), and Suicide Probability Scale (SPS) were used to evaluate the subjects in the MDD and control groups. In the first stage, serum nesfatin-1, ghrelin, and lipid levels were compared between the adolescents diagnosed with MDD and the control group. Next, the correlations between these levels and the CDI, SCARED, and SPS scores were evaluated. Results: Nesfatin-1 levels were significantly lower in the MDD group than the control group (p < 0.001) A positive correlation was found between the nesfatin-1 levels and the SPS scores. Conclusions: This is the first study to evaluate nesfatin-1 levels in adolescent depression, suggesting that nesfatin-1, ghrelin, total cholesterol, and low-density lipoprotein cholesterol (LDL) levels can be used as biomarkers in child-adolescent MDD. However, it is evident that further studies with larger samples and post-treatment measurements are needed.
- 4 June 2020
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 74 (8) , 613-619
Serum nesfatin-1, ghrelin, and lipid levels in adolescents with first episode drug naïve unipolar depression
Background: Major depressive disorder (MDD) is a mental health and emotional disorder that affects children and adolescents worldwide. This study aimed to evaluate serum nesfatin-1, ghrelin, and lipid levels as biological markers of adolescent MDD and their relationship with the severity of depression-anxiety and suicide risk in MDD. Methods:This study included 37 drug naïve adolescents between the ages of 12 and 18 who were diagnosed with a first episode MDD according to the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL) and DSM-V diagnostic criteria. Thirty-three healthy adolescents between the ages of 12 and 18 were included as the control group. The Children’s Depression Inventory (CDI), Screen for Child Anxiety Related Disorders (SCARED), and Suicide Probability Scale (SPS) were used to evaluate the subjects in the MDD and control groups. In the first stage, serum nesfatin-1, ghrelin, and lipid levels were compared between the adolescents diagnosed with MDD and the control group. Next, the correlations between these levels and the CDI, SCARED, and SPS scores were evaluated. Results: Nesfatin-1 levels were significantly lower in the MDD group than the control group (p < 0.001) A positive correlation was found between the nesfatin-1 levels and the SPS scores. Conclusions: This is the first study to evaluate nesfatin-1 levels in adolescent depression, suggesting that nesfatin-1, ghrelin, total cholesterol, and low-density lipoprotein cholesterol (LDL) levels can be used as biomarkers in child-adolescent MDD. However, it is evident that further studies with larger samples and post-treatment measurements are needed.